Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2000 participants
OBSERVATIONAL
2007-10-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Host Immunity, Plasmodium and Pathogens Co-Infections
NCT06769815
Post-discharge Malaria Chemoprevention(PMC) Study
NCT02671175
Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission
NCT07246525
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin
NCT05650502
Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali
NCT03035305
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Cases: Severe inpatient malaria, survivors or decedents. Severe malaria consists of any one or combination of severe malarial anemia (SMA), cerebral malaria (CM), lactic acidosis (LA), or a respiratory distress syndrome with hypoxia.
No interventions assigned to this group
2
Controls: Controls consist of mildly-affected children with P falciparum malaria who are either managed as inpatients or outpatients.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
6 Months
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Toronto
OTHER
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Health Network
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicolette Nabukeera-Barungi, MBChB, MMEd
Role: STUDY_DIRECTOR
Mulago Hospital/Makerere University (lead local investigator)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mulago Hospital Acute Care Unit & Makerere University Department of Paediatrics & Child Health
Kampala, , Uganda
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cserti CM, Dzik WH. The ABO blood group system and Plasmodium falciparum malaria. Blood. 2007 Oct 1;110(7):2250-8. doi: 10.1182/blood-2007-03-077602. Epub 2007 May 14.
Cserti-Gazdewich CM, Dzik WH, Dorn ME, Quagliaroli RO, Xu S, Ssewanyana I, Nayyar R, Preffer FI. Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: application to the study of Plasmodium falciparum malaria. Cytometry B Clin Cytom. 2009 Mar;76(2):127-34. doi: 10.1002/cyto.b.20443.
Cserti-Gazdewich CM, Dhabangi A, Musoke C, Ssewanyana I, Ddungu H, Nakiboneka-Ssenabulya D, Nabukeera-Barungi N, Mpimbaza A, Dzik WH. Inter-relationships of cardinal features and outcomes of symptomatic pediatric Plasmodium falciparum MALARIA in 1,933 children in Kampala, Uganda. Am J Trop Med Hyg. 2013 Apr;88(4):747-756. doi: 10.4269/ajtmh.12-0668. Epub 2013 Jan 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HS 356
Identifier Type: -
Identifier Source: secondary_id
ISBT 777531237
Identifier Type: -
Identifier Source: secondary_id
07-0548-AE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.